Patent office announces final rule on claims
WASHINGTON The U.S. Patent and Trademark Office has issued a new rule that will change how many claims patent applications may contain, as well as how many continuing applications applicants may file.
The new rule requires that any third or subsequent continuing application that is a continuing application or a continuation-in-part application, and any second or subsequent request for continued examination in an application family, be filed to obtain consideration of an amendment, argument, or evidence, and be supported by a showing as to why the amendment, argument, or evidence sought to be entered could not have been previously submitted.
The revised rules also require an applicant to file an examination support document that covers all of the claims in an application if the application contains more than five independent claims or more than twenty-five total claims.
The new rule will go into effect on Nov. 1.
Scientists show correlation between statins and Alzheimer’s treatments
HASBRUCK HEIGHTS, N.J. Scientists have found proof showing an association between statin use and neuropathologic changes in the brain linked to Alzheimer’s disease.
The study was recently published in a brain disease report conducted by researchers at the University of Washington, the Veterans Affairs Puget Sound Health Care System and the Group Health Cooperative of Puget Sound.
Nymox Pharmaceuticals holds the worldwide patent for the use of statin drugs for the prevention and treatment of Alzheimer’s. The global market for statins exceeds over $25 billion. Alzheimer’s currently affects more than 4.5 million people in the United States, according to government estimates.
PDL to sell rights to drugs, cut related jobs
FREMONT, Calif. PDL BioPharma will sell the rights to four of its drugs and cut at least 250 jobs as the company moves it focus away from cardiovascular drugs to oncology and select immunological diseases.
The four drugs to be sold are Cardene, Ularitide, Retavase and IV Busulfex. The drugs produced $187.2 in revenue in the year ending June 30. The 250 jobs would be eliminated as a result of selling the drugs, but more job cuts could be expected as the company shifts its focus to diseases like multiple sclerosis.
The company has been under fire recently by its shareholders for keeping Mark McDade as chief executive officer even though he moved the company to a more expensive location and for being in charge while the company missed earnings and sales projections.